Cd101 Antibody

What is CD101 and where is it expressed in the human immune system?

CD101, also known as V7 antigen, is a member of the immunoglobulin (Ig) superfamily that functions as a disulfide-linked homodimer. Expression of CD101 is found on multiple immune cell populations including monocytes, granulocytes, and dendritic cells (particularly Langerhans-like cells expressing HLA-DR, CD1a, and CD1c markers) . Additionally, CD101 is expressed on T lymphocytes where it plays an important role in cell activation processes. Recent research has also identified CD101 expression on a subpopulation of regulatory T cells (CD4+, CD25+, Foxp3+) that demonstrate high suppressor activity in mouse models, though studies have not confirmed higher suppressor activity in the human CD101+ population .

What are the established applications for CD101 antibodies in immunological research?

CD101 antibodies, particularly the monoclonal antibody BB27, have multiple validated research applications:

• Flow cytometric analysis: Used for phenotyping and quantifying CD101-expressing cells in peripheral blood and other tissues, with recommended usage at ≤0.5 μg per test (defined as the amount of antibody that will stain a cell sample in a final volume of 100 μL)

• Immunoprecipitation: For isolation and purification of CD101 protein complexes

• Immunohistochemical staining: Primarily on frozen tissue samples for visualization of CD101 expression patterns

Researchers should note that optimal antibody concentrations should be empirically determined, as cell numbers can range from 10^5 to 10^8 cells/test depending on the experimental design .

How should CD101 antibodies be optimized for flow cytometry experiments?

For optimal results in flow cytometry applications, researchers should consider the following methodological approach:

• Titration assessment: The CD101 antibody (such as BB27 clone) should be carefully titrated to determine optimal concentration for specific cell populations. Starting at ≤0.5 μg per test is recommended .

• Sample preparation considerations:

  • Cell numbers should be empirically determined based on the specific cell type and expected CD101 expression level

  • Standard sample volumes should be 100 μL

  • Cell concentrations can range from 10^5 to 10^8 cells/test

• Validation controls:

  • Include isotype controls to account for non-specific binding

  • Consider using both CD101-positive (monocytes, activated T cells) and CD101-negative cell populations as biological controls

  • When studying specific subpopulations, use additional markers to properly identify the target cells (e.g., CD4, CD25, and Foxp3 for regulatory T cells)

• Quality control parameters:

  • Confirm antibody purity is >90% (as determined by SDS-PAGE)

  • Ensure aggregation is <10% (as determined by HPLC)

  • Verify proper filtration (0.2 μm post-manufacturing filtered)

What markers should be co-analyzed with CD101 for comprehensive immune cell phenotyping?

Based on current research, the following marker combinations provide robust phenotyping when studying CD101-expressing cells:

For T cell populations:

• CD4+ T cells: CD45RA, CCR7, CD101 to identify effector memory populations

• CD8+ T cells: CD45RA, CCR7, CD101, CXCR4, CCR5 to identify effector and memory subsets with HIV co-receptor expression

• Regulatory T cells: CD25, CD127, Foxp3, Helios, CD101, CTLA-4, CD39, Ki-67 to assess activation state and proliferation potential

For dendritic cell populations:

• CD1c+ DCs: CXCR4, CD101

• CD141+ DCs: CD101, CD40, CD80

For monocyte populations:

• Classical monocytes: CCR5, CD101

• Intermediate monocytes (CD14++CD16+): CCR5, CD101

• Non-classical monocytes (CD14+CD16++): CD101, CD40

This comprehensive approach allows researchers to distinguish between different cell subpopulations and their activation states while monitoring CD101 expression.

How does CD101 modulate T cell activation and function?

CD101 plays a complex role in T cell activation pathways:

• CD101 appears to have an activating function in specific T cell contexts. CD101+ CD28+ cells show heightened responsiveness to CD28 signaling. In experimental settings, anti-CD101 antibodies can increase T cell proliferation when combined with anti-CD28 or suboptimal levels of anti-CD3 stimulation, suggesting an activating role .

• Paradoxically, the monoclonal antibody BB27 has demonstrated inhibitory effects on T cell reactivity in allogeneic and antigen-specific mixed dendritic cell-T cell cultures, indicating context-dependent functionality .

• Transcriptomic analyses have shown that CD101 genetic variants are associated with altered expression of genes involved in antiviral pathways and HIV resistance, suggesting a role in modulating immune responses to viral pathogens .

• Functional assays reveal that CD101+ T cells from individuals with CD101 genetic variants display more proinflammatory phenotypes, with increased cytokine production compared to those without such variants .

This dual nature of CD101 signaling (both activating and regulatory) suggests its critical role in maintaining immune homeostasis through complex mechanisms that warrant further investigation.

What is the relationship between CD101 expression and regulatory T cell function?

The relationship between CD101 and regulatory T cell (Treg) function is multifaceted:

• In mouse models, CD101 is expressed on a subset of regulatory T cells (CD4+, CD25+, Foxp3+) that demonstrate high suppressor activity .

• In humans, CD101 is expressed on approximately 30% of Foxp3+ cells in peripheral blood mononuclear cells (PBMCs), though studies have not confirmed enhanced suppressor activity specifically within the human CD101+ Treg population .

• Research examining genetic variants in CD101 has revealed that individuals with Ig-like domain variants show:

  • Increased frequencies of CD101+ Treg cells expressing activation and proliferation markers CTLA-4, CD39, or Ki-67

  • Reduced capacity of Treg cells to suppress IL-2+CD4+ T cells compared to individuals without CD101 functional variants

• Additionally, individuals with cytoplasmic domain variants in CD101 demonstrate reduced frequency of Helios+Foxp3+ Treg cells among total Treg populations, suggesting potential deficits in immunoregulation .

These findings indicate that while CD101 marks regulatory T cells with potentially enhanced suppressive capacity, genetic variants in CD101 may impair this regulatory function, contributing to altered inflammatory homeostasis.

How do genetic variants in CD101 impact immune cell phenotypes and function?

Research has identified significant differences in immune cell phenotypes and functions associated with CD101 genetic variants:

Table 4.1: Selected Immune Cell Alterations Associated with CD101 Ig-like Variants

Key findings include:

• Individuals with Ig-like domain variants show:

  • Increased proportions of CD101-expressing CD8+ T cells and CD4+ T cells

  • Elevated frequencies of activated CD101+CD8+CD45RA+CCR7−CD38+ T effector memory (TEMRA) cells

  • Increased proportions of CD101+ Treg cells expressing activation markers (CTLA-4, CD39, Ki-67)

  • Reduced proportions of CD101+CD141+ dendritic cells and non-classical monocytes

  • Increased proportion of classical and intermediate monocytes expressing CCR5 (an HIV-1 co-receptor)

• Individuals with cytoplasmic domain variants exhibit:

  • Similar changes in Treg cell and DC subset phenotypes compared to those with Ig-like variants

  • Reduced frequency of Helios+Foxp3+ Treg cells among total Treg populations

  • Marked reduction in plasmacytoid DCs co-expressing CCR5 and CD40

These alterations collectively suggest that CD101 genetic variants modify immune homeostasis toward a more proinflammatory environment, potentially explaining the observed association with increased HIV-1 acquisition risk .

What methodological approaches can be used to assess CD101's role in inflammatory regulation?

To investigate CD101's role in inflammatory regulation, researchers can employ several methodological approaches:

• Genetic association studies:

  • Identify individuals with specific CD101 genetic variants (e.g., Ig-like domain variants such as rs12093834, rs17235773, or cytoplasmic domain variants such as rs34248572, rs150494742)

  • Compare immune phenotypes between variant carriers and non-carriers

• Multiparameter flow cytometry:

  • Design comprehensive antibody panels including CD101 alongside lineage markers, activation markers, and functional molecules

  • Analyze data using both conventional manual gating and unbiased clustering algorithms like FAUST (Full Annotation Using Shape-constrained Trees)

  • Quantify the frequency and phenotype of CD101+ cells across different immune populations

• Functional suppression assays:

  • Isolate Treg cells from individuals with and without CD101 variants

  • Co-culture with effector T cells at different ratios

  • Measure suppression of cytokine production (particularly IL-2) and proliferation

• Transcriptomic analysis:

  • Perform RNA sequencing on sorted immune cell populations from individuals with different CD101 genotypes

  • Compare gene expression profiles focusing on inflammatory pathways, antiviral responses, and immune regulation

• Cytokine production assays:

  • Stimulate PBMCs or sorted cell populations with various stimuli (e.g., anti-CD3/CD28, PMA/ionomycin)

  • Measure cytokine production via intracellular cytokine staining or multiplex bead arrays

  • Compare cytokine profiles between individuals with and without CD101 variants

These complementary approaches allow researchers to comprehensively assess how CD101 contributes to inflammatory homeostasis and how genetic variants may disrupt this regulation.

How might CD101 expression and variants contribute to HIV-1 acquisition risk?

Research suggests several mechanisms by which CD101 expression and genetic variants may influence HIV-1 acquisition risk:

• Altered co-receptor expression:

  • Individuals with CD101 Ig-like variants show increased frequencies of cells expressing the HIV-1 co-receptors CCR5 and CXCR4

  • Classical and intermediate monocytes from individuals with Ig-like variants demonstrate elevated CCR5 expression, potentially increasing cellular susceptibility to HIV-1 infection

• Impaired immunoregulation:

  • Despite increased frequencies of CD101+ Treg cells, individuals with Ig-like variants show reduced Treg suppressive capacity, particularly for IL-2+CD4+ T cells

  • This regulatory deficit may contribute to a more proinflammatory environment that favors HIV-1 replication and spread

• Increased baseline inflammation:

  • CD101 variants are associated with increased prevalence of proinflammatory phenotypes across multiple immune cell types

  • Conventional CD4+ and CD8+ T cells from individuals with CD101 variants show enhanced proinflammatory cytokine expression

  • Transcriptional profiles reveal alterations in antiviral pathways and HIV resistance genes in individuals with CD101 variants

• Modified dendritic cell function:

  • Individuals with cytoplasmic variants show marked reduction in plasmacytoid DCs co-expressing CCR5 and CD40, potentially altering type I interferon responses critical for antiviral immunity

Collectively, these findings suggest that CD101 contributes to homeostatic regulation of inflammation, with variants potentially increasing HIV-1 acquisition risk by creating a more permissive environment for viral infection and replication.

What research areas remain unexplored regarding CD101's role in human immunity?

Despite significant advances, several important research questions about CD101 remain to be addressed:

• Structure-function relationships:

  • How do specific genetic variants in different domains (Ig-like vs. cytoplasmic) mechanistically alter CD101 protein function?

  • What signaling pathways are differentially affected by these variants?

• Ligand identification:

  • The natural ligand(s) for CD101 remain unidentified

  • Characterizing these interactions could provide crucial insights into CD101's immunoregulatory mechanisms

• Tissue-specific functions:

  • Most studies have focused on circulating immune cells

  • Investigation of CD101's role in tissue-resident immune cells, particularly at barrier sites relevant to HIV transmission, is needed

• Therapeutic potential:

  • Can targeting CD101 modulate inflammatory responses in a therapeutic context?

  • Might CD101-targeted interventions alter susceptibility to HIV or other pathogens?

• Broader disease associations:

  • Beyond HIV, are CD101 variants associated with other infectious or inflammatory conditions?

  • Could CD101 expression serve as a biomarker for disease susceptibility or progression?

• Developmental regulation:

  • How is CD101 expression regulated during immune cell development and differentiation?

  • What transcription factors and epigenetic mechanisms control CD101 expression?

Addressing these research gaps will provide a more comprehensive understanding of CD101's role in immune homeostasis and potentially reveal new therapeutic targets for infectious and inflammatory diseases.

What are the optimal protocols for investigating CD101 expression across different immune cell subsets?

For comprehensive analysis of CD101 expression across immune cell populations, researchers should consider this methodological workflow:

• Sample preparation:

  • For peripheral blood: Isolate PBMCs using density gradient centrifugation

  • Cryopreserve in FBS with 10% DMSO if immediate analysis is not possible

  • Upon thawing, rest cells for 1-2 hours in complete media before staining

• Panel design for multiparameter flow cytometry:

  T cell panel:

  • Lineage markers: CD3, CD4, CD8

  • Memory/differentiation markers: CD45RA, CCR7

  • Activation markers: CD25, HLA-DR, CD38

  • Regulatory markers: CD127, Foxp3, Helios

  • Functional markers: CTLA-4, CD39, Ki-67

  • HIV-relevant markers: CCR5, CXCR4

  • Target molecule: CD101

  Myeloid cell panel:

  • Lineage markers: CD14, CD16 (monocytes); CD1c, CD141 (DCs)

  • Activation markers: CD40, CD80

  • HIV-relevant markers: CCR5, CXCR4

  • Target molecule: CD101

• Staining protocol:

  • Surface staining: Perform at 4°C for 30 minutes

  • For intracellular markers (Foxp3, Ki-67): Use appropriate fixation/permeabilization kit

  • Include viability dye to exclude dead cells

  • Use fluorescence minus one (FMO) controls for accurate gating

• Analysis approach:

  • Conventional manual gating following established hierarchical strategies

  • Consider complementary unbiased analyses using algorithms like FAUST

  • For rare populations, collect sufficient events (minimum 1-2 million total events)

• Validation approaches:

  • Confirm CD101 expression patterns using alternative detection methods (e.g., immunohistochemistry, Western blot)

  • Consider cell sorting of CD101+ and CD101- populations followed by functional assays

This comprehensive methodology enables reliable assessment of CD101 expression patterns and their correlation with functional phenotypes across diverse immune cell subsets.

How can functional assays be optimized to investigate CD101's role in immune regulation?

To effectively assess CD101's functional impact on immune regulation, researchers should consider these optimized assay protocols:

• Regulatory T cell suppression assay:

  Cell preparation:

  • Sort CD4+CD25hiCD127lo Treg cells from donors with defined CD101 genotypes

  • Sort CD4+CD25- conventional T cells (Tconvs) as responder cells

  • Label Tconvs with proliferation dye (e.g., CFSE or CellTrace Violet)

  Assay setup:

  • Co-culture Tregs and Tconvs at various ratios (1:1, 1:2, 1:4, 1:8)

  • Stimulate with anti-CD3/CD28 beads or plate-bound antibodies

  • Include Tconv-only wells as controls

  Readouts:

  • Proliferation: Measure dye dilution by flow cytometry after 3-5 days

  • Cytokine production: Assess IL-2 production by intracellular staining or ELISA

  • Activation markers: Evaluate CD25, CD69 upregulation

• T cell stimulation assays:

  Cell preparation:

  • Isolate total T cells or specific subsets based on CD101 expression

  • Use magnetic separation or flow sorting for highest purity

  Stimulation conditions:

  • Anti-CD3 alone (suboptimal)

  • Anti-CD3 plus anti-CD28

  • Anti-CD3 plus anti-CD101

  • Anti-CD3 plus anti-CD28 plus anti-CD101

  • PMA/ionomycin as positive control

  Readouts:

  • Proliferation: Measured by dye dilution or Ki-67 expression

  • Cytokine production: IFN-γ, TNF-α, IL-2, IL-4, IL-17

  • Activation markers: CD25, CD69, HLA-DR

• Mixed dendritic cell-T cell cultures:

  Cell preparation:

  • Isolate DCs and T cells from allogeneic donors or use autologous cells with antigen

  • Consider CD101 expression and genetic variant status

  Assay setup:

  • Co-culture DCs and T cells at defined ratios

  • Include anti-CD101 antibody (BB27) in test conditions

  • Include isotype control antibodies

  Readouts:

  • T cell proliferation

  • Cytokine production

  • Expression of activation markers

• Transcriptomic analysis:

  Sample preparation:

  • Sort cells based on CD101 expression and genotype

  • Extract high-quality RNA using validated protocols

  Analysis approaches:

  • RNA sequencing with sufficient depth (>20M reads per sample)

  • Focus on pathways relevant to inflammation, antiviral responses, and HIV resistance

  • Validate key findings with RT-qPCR and protein-level assays